🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise globally, with data suggesting more than 82 million new cases per year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

Based on findings released by a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have expressed optimism. Having a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as vital to reduce the burden of the infection for people and to stop the proliferation of untreatable gonorrhoea around the world.